Cost-effectiveness of government nutrition assistance program policies in childhood obesity prevention
Methods: The CHildhood Obesity Intervention Cost-Effectiveness Study (CHOICES) microsimulation model and systematic review process was used to estimate the impact and cost-effectiveness of three nutrition policies targeting SNAP and WIC. Healthcare costs averted and the cost-effectiveness of ten-year reductions in per capita body mass index (BMI), childhood obesity prevalence, and gains in quality-adjusted life years (QALYs) were estimated for the 2015 U.S. population.
Results: Implementing these three policies would cost between $124 million and $528 million, and would reach 4.4 million to 20 million mostly low-income children in the first year. These interventions are estimated to reduce BMI by, on average, 0.042 – 0.1 units per person. Over a ten-year period these interventions are estimated to cost $91 to $497 per BMI unit reduced. Results on healthcare costs and cost-effectiveness to reduce childhood obesity and increase QALYs will be presented.
Conclusions: Changes to the federal nutrition assistance programs have varying results on BMI and reach, depending on program population and strategy. In comparison to clinical interventions, these policies can still be potentially cost-effective initiatives for reducing population BMI.
Learning Areas:Conduct evaluation related to programs, research, and other areas of practice
Public health or related public policy
Evaluate and compare the cost and effectiveness of three interventions involving government nutrition assistance programs (SNAP and WIC) on reducing childhood obesity.
Keyword(s): Obesity, Policy/Policy Development
Qualified on the content I am responsible for because: I have a masters degree in public health with a concentration in obesity epidemiology and prevention. I have several years of experience conducting childhood obesity intervention cost-effectiveness research.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.